Peripheral Treg Cell Senescence & Serum Total Cholesterol Level
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05680844|
Recruitment Status : Recruiting
First Posted : January 11, 2023
Last Update Posted : March 30, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Observational Study of the Correlation Between Peripheral Treg Cell Senescence and Serum Total Cholesterol Level|
|Actual Study Start Date :||January 1, 2023|
|Estimated Primary Completion Date :||March 31, 2023|
|Estimated Study Completion Date :||March 31, 2023|
normal cholesterol level group
Serum total cholesterol level of < 5.17 mmol/L
Serum total cholesterol level of >= 5.17 mmol/L
- Treg cell senescence [ Time Frame: After confirming the subject has signed the informed consent, and recorded the past medical history and medication (especially hypolipidemic drugs) in the past 3 months. ]Treg cell senescence will be evaluated by the beta-galactosidase (SA-betagal) activity test
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||30 Years to 60 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Probability Sample|
- Age ≥ 30 and ≤ 60 years old with independent behavior ability.
- The participants need to fully understand the purpose and content of the study, and voluntarily participate in the study and sign the informed consent.
- Pregnant or lactating women.
- Acute and severe diseases in the last 3 months, including but not limited to, acute myocardial infarction, acute cerebral infarction, cerebral hemorrhage, circulatory failure, respiratory failure (internal diseases), trauma requiring hospitalization, or undergoes surgery under general anesthesia (surgical diseases).
- History of severe diseases, including but not limited to, tumors, serious hematological diseases, serious cardiopulmonary diseases (interventional therapy for coronary artery disease, atrial fibrillation, chronic obstructive pulmonary disease, etc.), renal failure, liver failure, old stroke with serious sequelae.
- Have participated in clinical trials in the past 3 months.
- The investigator considers that not appropriate for inclusion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05680844
|Contact: Xintong Ge, M.D.||email@example.com|
|Tianjin Medical University General Hospital||Recruiting|
|Tianjin, Tianjin, China, 300052|
|Contact: Xintong Ge, M.D.|
|Principal Investigator:||Ping Lei, Ph.D.||Tianjin Medical University General Hospital|
Documents provided by Xintong Ge, Tianjin Medical University General Hospital:
|Responsible Party:||Xintong Ge, Professor, Tianjin Medical University General Hospital|
|Other Study ID Numbers:||
|First Posted:||January 11, 2023 Key Record Dates|
|Last Update Posted:||March 30, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Lipid Metabolism Disorders